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Functional Modulation of IGF-Binding Protein-3
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Altaf A. Dar1, Shahana Majid2, Mehdi Nosrati1, David de Semir1, Scot Federman1 and Mohammed Kashani-Sabet1
IGF-binding protein-3 (IGFBP3) is a member of the IGFBP family, which regulates mitogenic and antiapoptotic
effects of IGFs. In this report we evaluated the role of IGFBP3 in melanoma. Quantitative real-time PCR
(qRT-PCR), western blot, and ELISA analyses indicated a significant downregulation of IGFBP3 expression in
melanoma cell lines as compared with a normal melanocyte cell line. Melanoma cell lines treated with the
demethylating agent 5-AZA-20-deoxycytidine reexpressed IGFBP3 at the mRNA and protein levels. Chromatin
immunoprecipitation assays revealed enrichment of acetylated histones H3 and H4, and H3 di- and tri-methylated
lysine 4 on the unmethylated IGFBP3 promoter. The IGFBP3 promoter region was highly methylated in human
melanoma samples as compared with normal nevi. Overexpression of IGFBP3 in melanoma cells in vitro
suppressed tumor cell survival, induced apoptosis, reduced colony formation and invasion, and induced
expression of the proapoptotic genes p21, PUMA, and BAX. IGFBP3 overexpression also resulted in cleavage of
caspase 3 and reduced expression of phosphorylated AKT. Stable overexpression of IGFBP3 suppressed tumor
cell growth in vivo. Our study results indicate that silencing of IGFBP3 in melanoma is due to the methylation of
its promoter, and that overexpression of IGFBP3 induces apoptosis and suppresses cell survival and growth.
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INTRODUCTION
Melanoma is the sixth most common cancer in the USA,
accounting for more than 60,000 new cases each year
(Wargo and Tanabe, 2009) and its incidence has been
increasing rapidly in Western countries (Tucker and
Goldstein, 2003). Recent efforts have focused on the
discovery of genes that may have a central role in mela-
noma progression by using high-throughput gene expression
analysis (Gutgemann et al., 2001; Haqq et al., 2005). Several
genetic changes associated with melanoma have also been
identified (Chin, 2003). These approaches have helped to
identify numerous potential disease progression markers in
both in vivo and in vitro model systems of melanoma (Bittner
et al., 2000).
Transcriptional inactivation by cytosine methylation at
promoter CpG islands of tumor suppressor genes (TSGs) is an
important mechanism in human carcinogenesis (Laird, 2005).
To date, there have been limited studies addressing the role of
epigenetic changes during melanoma progression, or evaluat-
ing differences in the epigenetic patterns of primary versus
metastatic tumors. However, epigenetic inactivation of TSGs
has been implicated in tumorigenesis and in the progression
of different malignancies (Herman and Baylin, 2003; Kusano
et al., 2006) in addition to mutations and loss of hetero-
zygosity (Kane et al., 1997). A number of genes have been
reported epigenetically silenced in melanoma, including
PTEN, RARB, RASSF1A, MGMT, DAPK, CDKN2A, p27,
and SOCS1 (Balch et al., 2001; Guan et al., 2003; Spugnardi
et al., 2003; Worm et al., 2004; Mirmohammadsadegh et al.,
2006).
The IGF-binding protein (IGFBP) superfamily, which
includes the IGFBP-related proteins, regulates the bioavail-
ability of insulin and IGF. IGFBP3 is one member of this
family, and has been shown to inhibit cell proliferation in
breast, lung and prostrate cancer cells, and in some cell lines
to reduce tumor growth (Hwa et al., 1999). IGFBP3 is
reported to be a growth suppressor by virtue of its effects on
multiple pathways (De Mellow and Baxter, 1988; Valentinis
et al., 1995). In the IGF receptor-dependent pathways,
IGFBP3 binds to IGF-1, 2 and suppresses its growth signal
(De Mellow and Baxter, 1988). In the IGF receptor-
independent pathways, IGFBP3 mediates a wide variety of
growth suppression signals such as TGFb, retinoic acid,
tumor suppressor protein p53, vitamin D, antiestrogens, and
tumor necrosis factor-a (Oh et al., 1993; Buckbinder et al.,
1995; Martin et al., 1995; Gucev et al., 1996). IGFBP3-
mediated growth inhibitory effects were reversed when its
expression was repressed by antisense DNA (Gucev et al.,
1996). The observation that the overexpression of IGFBP3
increases apoptosis suggests that it may function as a
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potential tumor suppressor. The inactivation of TSGs is one of
the most important mechanisms responsible for tumorigen-
esis. TSGs can be functionally inactivated by epigenetic
alterations like promoter methylation and histone deacetyla-
tion (Merlo et al., 1995) in addition to deletions or point
mutations. Promoter hypermethylation of IGFBP3 has been
reported to silence it epigenetically in hepatocellular
carcinoma (Hanafusa et al., 2002), non-small cell lung
carcinoma (Chang et al., 2002), and bladder and ovarian
cancers (Christoph et al., 2006; Wiley et al., 2006). Recently,
interindividual variations in IGFBP3 levels have been
reported to be genetically determined by a polymorphism
at the 202 locus of IGFBP3, and have been associated with
increased risk of different cancers (Le Marchand et al., 2005;
Moon et al., 2006).
In this study we show silencing of IGFBP3 in melanoma,
and examine the functional role of IGFBP3 overexpression
in vitro and in vivo.
RESULTS
Expression of IGFBP3 in melanoma cell lines and tissues
We analyzed expression of IGFBP3 in different human
melanoma cells lines by quantitative real time-PCR (qRT-
PCR) and western blot analyses, and compared it with a
normal melanocyte cell line. IGFBP3 was significantly
downregulated both at the mRNA and the protein levels in
all melanoma cell lines examined as compared with normal
melanocytes (Figure 1a and b). However, there was a
difference in the IGFBP3 expression level among the different
melanoma cell lines. We further analyzed expression of
secreted IGFBP3 in these cell lines using ELISA, and
confirmed reduced levels of IGFBP3 in melanoma cells
compared with normal melanocytes (Figure 1c). To deter-
mine the level of IGFBP3 expression in tissues, we analyzed
its expression in human melanoma (n¼36) and normal nevus
samples (n¼26). IGFBP3 expression was significantly down-
regulated in tumor samples when compared to nevi (Figure
1d). The knockdown of IGFBP3 in cell lines and in tumor
samples shows that IGFBP3 is silenced in melanoma.
Effect of 5-AZA-20-deoxycytidine on IGFBP3 expression and
chromatin modifications
To investigate whether the silencing of IGFBP3 expression in
melanomas might be due to DNA hypermethylation, we
treated a panel of five melanoma cell lines with the DNA
methyltransferase inhibitor 5-AZA-20-deoxycytidine (5AZA).
IGFBP3 expression was significantly upregulated at the
mRNA and protein levels after 5 mM 5AZA treatment (Figure
2a and b). Treatment of cells at a lower concentration of
5AZA (1 mM) did not show any significant induction of
IGFBP3 (data not shown). These results suggest that silencing
of IGFBP3 is due, at least in part, to DNA hypermethylation.
To determine whether there were covalent chromatin
changes after 5AZA treatment at the IGFBP3 locus, we
performed chromatin immunoprecipitation analysis with
various antibodies as described in Materials and Methods.
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Figure 1. Expression of IGF-binding protein-3 (IGFBP3) mRNA and protein in cell lines and human specimens. mRNA and protein expression levels of IGFBP3
in a normal melanocyte cell line and six melanoma cell lines as determined by qRT-PCR (a) and western blot analysis (b). (c) Secreted IGFBP3 levels in different
melanoma cell lines as determined by enzyme-linked immunosorbent assay. (d) Expression of IGFBP3 at the mRNA level quantified by qRT-PCR in nevus
(n¼26) and melanoma (n¼ 36) samples. *Po0.001.
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5AZA treatment resulted in enrichment of acetylated histones
H3, H4, and H3 di- and tri-methylated lysine 4 close to the
IGFBP3 transcription start site in C8161.9 melanoma cells
(Figure 2c and d). These chromatin changes are indicative of
activation of gene expression. Thus, the promoter demethyla-
tion and increased IGFBP3 expression caused by 5AZA
treatment correlated with active histone modifications at the
IGFBP3 transcription start site in melanoma cells. However,
in MaMel144a1 cells, no significant increase in IGFBP3
reexpression was observed at the mRNA and protein levels
after 5AZA treatment, indicating that other mechanisms such
as acetylation, or translational or posttranslational modifica-
tions may be involved to regulate its expression.
Methylation status of IGFBP3 promoter
To determine whether transcriptional silencing of the IGFBP3
gene is due to promoter hypermethylation, we analyzed the
methylation status of the IGFBP3 promoter in melanoma cell
lines, 15 tumor and 10 nevus samples by bisulfite-modified
PCR followed by direct sequencing of the modified DNA
samples. We used MethPrimer software (Li and Dahiya,
2002) to select primers in the CpG-rich region of the IGFBP3
promoter (Figure 3a). Primers were designed with no CpG
sites in either the forward or the reverse primer; as a result,
amplification proceeds in a manner unbiased by promoter
methylation status. As shown in Figure 3a, the IGFBP3
promoter was highly methylated in C8161.9 and DO4
melanoma cells, which was reversed by 5AZA treatment
(Figure 3b and c). DNA isolated from nevi and primary
melanomas was modified by bisulfite, and the IGFBP3
promoter region in melanomas was found to be highly
methylated as compared with the promoter region of nevi
(Figure 4a and b). The PCR amplicons were subcloned from
untreated C8161.9 melanoma cells, as well as 5AZA-treated
nevi and melanoma samples, and five individual clones from
each group were sequenced. The resulting sequences from
the clones were compared with the parent promoter
sequence from which the clones were made, and the
methylation status of the CpG dinucleotides within this
amplicon was determined by characteristic chemical changes
associated with cytosines existing in either a methylated or an
unmethylated state. DNA sequences from the promoter
region of untreated C8161.9 cells (Figure 3d) and primary
melanomas (Figure 4b) were highly methylated, whereas the
promoter region of the 5AZA-treated C8161.9 cells (Figure
3d) and the nevus samples (Figure 4a) was completely
demethylated. These results indicate that transcriptional
silencing of the IGFBP3 gene is due to promoter hypermethy-
lation that can be reversed by 5AZA treatment.
Effect of IGFBP3 expression on melanoma cell growth and
apoptosis
To examine the biological role of IGFBP3 in melanoma cells,
we transiently transfected C8161.9 cells with a mammalian
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Figure 2. Effect of 5-AZA-20deoxycytidine treatment (5AZA) on IGF-binding protein-3 (IGFBP3) expression. Five melanoma cell lines (C8161.9, DO4,
WM3211, MaMel71, and MaMel144a1) were treated with 5AZA (5 mM), and IGFBP3 mRNA (a) and protein (b) expression levels were determined by qRT-PCR
and western blot analysis. (c) Effects of 5AZA on histone modifications of the IGFBP3 promoter. Chromatin immunoprecipitation assay was performed on
C8161.9 cells after treatment with 5AZA (5 mM). Acetylated H3 and H4 and methyl-2H3K4 and 3H3K4 levels in C8161.9 cells treated with 5AZA showed
significant enrichment compared with untreated cells. (d) Bar graph showing quantification of histone enrichment. Enrichment was calculated as the ratio
between the net intensity of each bound sample normalized to its input sample and the vehicle control sample normalized to vehicle control input samples.
www.jidonline.org 2073
AA Dar et al.
IGFBP3 Expression in Melanoma
expression vector expressing full-length human IGFBP3.
Overexpression of IGFBP3 was confirmed by western blot
analysis (Figure 5a). Because our earlier study results
indicated that IGFBP3 is silenced in melanoma cells and
tumor samples, we analyzed the effects of IGFBP3 over-
expression on melanoma cell growth and apoptosis. A cell
survival assay of C8161.9 cells overexpressing IGFBP3
showed significant suppression in growth as compared with
control vector-expressing cells (Figure 5b). Cell cycle analysis
and TUNEL assay confirmed that the growth suppression
observed in IGFBP3-overexpressing cells was, at least in part,
due to apoptosis (Figure 5c and d). A similar effect on cell
survival and apoptosis was observed in DO4 melanoma cells
(data not shown). IGFBP3 overexpression induced expression
of the proapoptotic genes p21, BAX and PUMA. Intriguingly,
there was no difference in the level of the p53 protein after
IGFBP3 overexpression. IGFBP3 overexpression was also
associated with cleaved caspase 3 and reduced levels of
phosphorylayted AKT (S437).
IGFBP3 overexpression inhibits colony formation, cell invasion,
and reduces tumor cell growth
To further examine the effects of IGFBP3 overexpression, we
generated C8161.9 cells stably expressing IGFBP3, and
confirmed the overexpression of IGFBP3 using western blot
analysis (Figure 6a). We chose two clones (Cl-3 and Cl-5)
overexpressing IGFBP3 to rule out clonal variability. Both
clones showed a significant suppression in cell growth as
compared with control vector-expressing cells (Figure 6b).
We observed a highly significant decrease in the colony
formation capability of IGFBP3-overexpressing clones as
compared with a control vector-expressing clone (Figure 6c).
In addition, both clones were found to show higher apoptotic
rates and reduced tumor cell invasion into Matrigel (Figure 6d
and e). Finally, stable overexpression of IGFBP3 dramatically
suppressed C8161.9 tumor growth in vivo on subcutaneous
injection into nude mice when compared to cells expressing
control vector. Both clones showed a similar pattern in the
reduction of tumor growth as compared with clones
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expressing vector control (Figure 6f). These results show the
functional role of IGFBP3 as a tumor suppressor in
melanoma.
DISCUSSION
Gene expression is modulated by both genetic and epigenetic
mechanisms. It is increasingly recognized that epigenetic
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changes are important in carcinogenesis (Baylin and Herman,
2000). Silencing of gene transcription by DNA methylation is
one of the most important mechanisms in mammalian cells
for selectively expressing a set of genes to maintain cell-type
specificity. Using candidate gene-based approaches, we
have analyzed several genes for promoter methylation in
melanoma (Gonzalgo et al., 1997; Worm et al., 2000).
Recognition of the importance of promoter hypermethylation
in human cancer has fostered a growing effort to screen the
cancer genome to identify methylated loci. In this study, we
evaluated the expression and methylation status of the
IGFBP3 gene in melanoma cell lines and human tumor
samples.
IGFBP3, a member of the IGFBP family of proteins, is
known to inhibit cell proliferation in vitro and to reduce
tumor growth in vivo (Hwa et al., 1999). Epigenetic silencing
of IGFBP3 by promoter methylation is reported in a number
of solid tumors (Hanafusa et al., 2002; Ibanez de Caceres
et al., 2006; Wiley et al., 2006; Tomii et al., 2007). We
determined the status of IGFBP3 and observed a significant
downregulation of IGFBP3 at the mRNA and protein levels in
melanoma cell lines as compared with a normal melanocyte
cell line, even though the relative expression of IGFBP3
varied among the different cell lines examined. Expression of
IGFBP3 mRNA in human primary melanomas was also
significantly downregulated when compared with nevi. These
observations indicate that IGFBP3 is silenced in melanoma
cell lines and in tumor samples. Because silencing could be
due to either genetic or epigenetic mechanisms, we
investigated whether silencing of IGFBP3 is due to promoter
methylation. Treatment of five melanoma cell lines with the
demethylating agent 5AZA led to reexpression of IGFBP3,
indicating that DNA encoding IGFBP3 is methylated. 5AZA
has been reported to demethylate DNA and restore gene
expression in cell culture (Bender et al., 1999). Aberrant DNA
methylation and histone modifications work together to
silence many TSGs in human cancers (Kristeleit et al.,
2004; Nakagawa et al., 2005). Hyperacetylation of histone
lysine residues has been shown to facilitate transcriptional
activation (Kristeleit et al., 2004) and to induce gene
expression (Archer and Hodin, 1999). The results of our
study revealed that 5AZA caused an increase in acetyl H3,
acetyl H4, 2H3K4, and 3H3K4 histones compared
with untreated control in melanoma cell lines. Enrich-
ment of these active chromatin modifications near the
transcription start site of the IGFBP3 gene is associated
with active gene expression. This transformation of
key parameters of the histone code on inhibition of the
DNA methyltransferases suggests that in melanoma cells,
DNA hypermethylation, or another activity mediated by
DNA methyltransferases, may be essential for maintaining a
particular combination of histone modification at gene
promoters silenced with aberrant DNA hypermethy-
lation. IGFBP3 methylation is proposed to occur at the early
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Figure 6. Stable overexpression of IGF-binding protein-3 (IGFBP3) suppresses colony formation, invasiveness, and tumor growth, and induces apoptosis.
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steps of tumorigenesis as it is important in cell proliferation
and apoptosis (Oh et al., 2002). DNA sequencing of
melanoma cell lines as well as tumor samples revealed the
hypermethylation status of IGFBP3 as confirmed by bisulfite
genomic sequencing. The IGFBP3 promoter region was
densely and heterogeneously methylated both in tumor
samples and in melanoma cell lines. By contrast, the IGFBP3
promoter was found to be completely unmethylated in nevus
samples.
Xi et al. (2006) reported higher expression of IGFBP3
in metastatic melanomas compared with primary tumors;
however, recently Yu et al. (2008) contradicted this
work. Their study data suggest no significant difference
in IGFBP3 expression in primary and metastatic samples.
In both studies, IGFBP3 expression was compared between
primary and metastatic samples, but not nevi. Recently,
Oy et al. (2010) reported silencing of IGFBP3 in mela-
noma cells lines and in patient samples, and showed
that IGFBP3 expression is regulated by PI3kinase/AKT and
MAPK/ERK1/2 pathways.
To date, a number of genes have been reported whose
expression is altered in melanomas by changes in methyla-
tion status. Furuta et al. (2004) reported the promoter
methylation status of 30 genes in melanoma. There are also
contradictory reports on methylation of certain genes in
melanomas, such asMGMT. For example, Hoon et al. (2004)
reported MGMT methylation in 4 of 15 cell lines and 31 of
106 tumors. In contrast, Paz et al. (2003) reported no
methylation of MGMT in 18 cell lines. PTEN, MTAP, and p27
(Worm et al., 2000; Zhou et al., 2000; Behrmann et al., 2003)
have also been reported to be methylated in melanomas.
To further understand the functional significance of
IGFBP3, we examined the effects of both transient and stable
IGFBP3 overexpression in melanoma cell lines. Overexpres-
sion of IGFBP3 resulted in a marked increase in apoptosis and
suppression of cell survival. IGFBP3 overexpression signifi-
cantly reduced levels of phosphorylated AKT, suggesting that
it is interacting with IGF, thus blocking their interaction with
their cell membrane receptors and resulting in suppression of
the IGF axis. Although p53 is known to induce IGFBP3
(Buckbinder et al., 1995), there was no significant effect on
p53 expression after IGFBP3 overexpression despite the
upregulation of p21, BAX, and PUMA following IGFBP3
overexpression. Taken together, the results of our study
suggest that these proapoptotic downstream targets of p53
may be activated through a p53-independent pathway. In
vivo studies further confirmed its role as tumor suppressor by
virtue of a striking reduction in tumor cell growth in mice
injected with C8161.9 cells overexpressing IGFBP3.
Although the apoptotic assays performed (cell cycle, cleaved
caspase 3 expression, and TUNEL) demonstrated the con-
tribution of increased apoptosis to melanoma cell growth
inhibition, the significant suppression of tumor cell invasion
in vitro suggests an additional mechanism for the observed
inhibition of in vivo tumor cell growth on IGFBP3 over-
expression.
In summary, we report that IGFBP3 is silenced in
melanoma. Overexpression of IGFBP3 resulted in suppres-
sion of melanoma cell growth and invasiveness, and
induction of apoptosis.
MATERIALS AND METHODS
Cell culture, 5-AZA-20-deoxycytidine treatment, and plasmids
The WM3211, DO4, WM1205, MaMel71, and MaMel144a1 (kindly
provided by Boris Bastian, UCSF, San Francisco, CA) melanoma
cell lines were grown in RPMI with 10% fetal bovine serum.
C8161.9 cells (obtained from Danny Welch) were grown in DMEM/
F12 with 5% fetal bovine serum (Invitrogen Life Technologies,
Carlsbad, CA) at 37 1C in an atmosphere containing 5% CO2.
Normal human melanocytes were grown in Medium 254 (Cascade
Biologics, Portland, OR). Subconfluent cells (60–70% confluent)
were treated with 5AZA (Sigma-Aldrich, St Louis, MO) dissolved in
dimethyl sulfoxide. Cells treated with vehicle served as the control.
5AZA was added every day along with a change of media, and the
cells were grown for 4 days. The pCMV6-entry (control) and
pCMV6-IGFBP3 plasmids were purchased from OriGene Technol-
ogies (Rockville, MD), and transfected transiently using Lipofecta-
mine 2000 (Invitrogen Life Technologies) following the
manufacturer’s protocol.
RNA/DNA extraction from formalin-fixed, paraffin-embedded
tissue samples and cell lines
Samples from patients with primary melanoma (n¼ 36) and benign
nevi (n¼ 26) presenting to the Melanoma Center were obtained
under a protocol approved by the UCSF Institutional Review Board.
Briefly, paraffin-embedded tissues were scraped from ten 5-mm
slides and deparaffinized with xylene followed by a wash with
ethanol (100%). RNA and DNA were extracted by using the
AllPrep DNA/RNA kit (Qiagen, Valencia, CA) following the
manufacturer’s protocol. RNA and DNA from cell lines were
extracted using the RNeasy Mini Kit and QIAamp DNA Mini Kit
(Qiagen), respectively.
Quantitative real-time PCR analysis
For quantitative real-time PCR (TaqMan assay; Applied Biosystems,
Foster City, CA), cDNA was synthesized from 200ng of DNase
I-digested total cellular RNA and the assay was performed as
previously described (Nosrati et al., 2004).
Cell cycle and cell viability assay
The cell cycle assay was performed as described (Dar et al., 2008).
For the cell survival assay, cells were plated in 96-well plates at a
density of 3 103 cells per well. The cell viability assay was
performed at 24, 48, 72, and 96 hours after transfection using Cell
Counting Kit 8 (Dojindo, Rockville, MD) following the manufac-
turer’s protocol.
Stable cell generation, colony formation assay, and in vivo study
C8161.9 cells were transfected with pCMV6-IGFBP3 or pCMV6-
entry vectors and selected with G418 (500mgml1) till colonies
formed. For the colony formation assay, 800 cells were plated in a
p100 plate and allowed to grow in the presence of G418
(500mgml1) till visible colonies appeared. Colonies were stained
with Giemsa and counted. For in vivo studies, 1 106 cells were
injected into nude mice subcutaneously and tumor growth was
followed for 29 days. All animal care was in accordance with the
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institutional guidelines approved by the University of California San
Francisco Committee on Animal Research.
Sodium bisulfite modification and sequencing
Bisulfite modification of DNA was performed using the Epi-Tect
Bisulfite kit (Qiagen) following the manufacturer’s protocol and
as previously described (Majid et al., 2009). Primers for bisulfite
genomic sequencing PCR were designed by using the online
program MethPrimer (Li and Dahiya, 2002). The primers used are
F1 (GTTGAGTTGGTTAGGAGTGATTG), F2 (TTTTTTTTAATTTTTAT
TTTTGGG), and R1 (AAACAACACCAACAAAATCAA).
Cloning for methylation confirmation
Bisulfite-modified DNA was amplified using primers F2 and R1
and the products were confirmed by electrophoresis. Amplified
products were cloned into the pCR2.1-Topo vector as described
(Majid et al., 2009).
Chromatin immunoprecipitation analysis
Chromatin immunoprecipitation analysis was performed using the
EZ-ChIP kit (Upstate Biotechnology, Charlottesville, VA) according
to the manufacturer’s directions and as previously described (Majid
et al., 2009). Antibodies were purchased from Upstate Biotechnology
and were specific for acetyl histone H3 (06-599), acetyl histone
H4 (06-866), dimethyl-histone H3 lysine 4 (07-030), and trimethyl-
histone H3 lysine 4 (07-473). The ImageJ software, version 1.36b,
(http://rsb.info.nih.gov/ij/) was used for optical densitometry. For
enrichment calculation, each sample was normalized with its
respective input samples and then the treated samples were
compared with their untreated controls for each used antibody
(Bound Sample/Bound Sample Input)/(Vehicle Control Sample/
Vehicle Control Input). The sequence of primers used for PCR was:
forward, 50-cccctggggatataaacagc-30; reverse, 50-gcattcgtgtgtacctcgtg-30.
TUNEL apoptosis assay
The TUNEL assay was carried out as per the manufacturer’s instructions
(Roche, Indianapolis, IN). Data acquisition and analysis were performed
on Becton Dickinson LARII (Becton Dickinson, San Jose, CA).
Western blot analysis
Cell lysates were prepared in phosphate-buffered saline containing
1 Halt protease inhibitor cocktail and 1 Halt phosphatase
inhibitor cocktail (Pierce, Rockford, IL) centrifuged at 3,500 r.p.m.
for 10minutes at 4 1C. Proteins (10–15 mg) from each sample were
subjected to SDS-PAGE and transferred onto a nitrocellulose
membrane. Target proteins were detected by using specific antibodies
against IGFBP3 and GAPDH (Santa Cruz Biotechnology, Santa Cruz,
CA), as well as AKT, pAKT (Ser473), PUMA, p21, BAX, p53, and
cleaved caspase 3 (from Cell Signaling Technology, Danvers, MA).
Statistical analysis
All quantified data represent an average of at least triplicate samples
or as indicated. Error bars represent standard deviation of the mean.
Statistical significance was determined using the Student’s t-test, and
P-values o0.05 were considered significant.
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